123 related articles for article (PubMed ID: 29740874)
1. Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity.
Shao N; Yu XY; Yu YM; Li BW; Pan J; Wu WH; Zhang HJ; Ma XF; Hao M; Kuang HY
Andrologia; 2018 Sep; 50(7):e13039. PubMed ID: 29740874
[TBL] [Abstract][Full Text] [Related]
2. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
[TBL] [Abstract][Full Text] [Related]
3. The effects of metformin and diet on plasma testosterone and leptin levels in obese men.
Ozata M; Oktenli C; Bingol N; Ozdemir IC
Obes Res; 2001 Nov; 9(11):662-7. PubMed ID: 11707532
[TBL] [Abstract][Full Text] [Related]
4. Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial.
Harreiter J; Just I; Leutner M; Bastian M; Brath H; Schelkshorn C; Klepochova R; Krššák M; Kautzky-Willer A
Diabetes Obes Metab; 2021 May; 23(5):1129-1139. PubMed ID: 33464703
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
6. Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus.
Quan H; Zhang H; Wei W; Fang T
J Diabetes Complications; 2016; 30(4):686-92. PubMed ID: 26873871
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
[TBL] [Abstract][Full Text] [Related]
8. The effect of testosterone on cardiovascular risk factors in men with type 2 diabetes and late-onset hypogonadism treated with metformin or glimepiride.
Krysiak R; Gilowski W; Okopień B
Pharmacol Rep; 2016 Feb; 68(1):75-9. PubMed ID: 26721356
[TBL] [Abstract][Full Text] [Related]
9. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
Miles JM; Leiter L; Hollander P; Wadden T; Anderson JW; Doyle M; Foreyt J; Aronne L; Klein S
Diabetes Care; 2002 Jul; 25(7):1123-8. PubMed ID: 12087008
[TBL] [Abstract][Full Text] [Related]
10. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Srivastava S; Saxena GN; Keshwani P; Gupta R
J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
[TBL] [Abstract][Full Text] [Related]
11. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
12. Effect of clomiphene citrate treatment on the Sertoli cells of dysmetabolic obese men with low testosterone levels.
Pelusi C; Fanelli F; Baccini M; Triggiani V; Bartolomeo N; Carbone MD; De Pergola G; Di Dalmazi G; Pagotto U; Pasquali R; Giagulli VA
Clin Endocrinol (Oxf); 2020 Jan; 92(1):38-45. PubMed ID: 31677181
[TBL] [Abstract][Full Text] [Related]
13. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
[TBL] [Abstract][Full Text] [Related]
14. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
15. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
Freemark M; Bursey D
Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
[TBL] [Abstract][Full Text] [Related]
16. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
Gu S; Deng J; Shi L; Mu Y; Dong H
J Med Econ; 2015; 18(10):808-20. PubMed ID: 25950193
[TBL] [Abstract][Full Text] [Related]
18. Neutral effect of exenatide on serum testosterone in men with type 2 diabetes mellitus: A prospective cohort.
Graybill S; Hatfield J; Kravchenko M; Beckman D; Tate J; Beauvais A; Clerc P; Davila D; Forbes W; Wardian J; Kemm M; Hubberd A; True M
Andrology; 2021 May; 9(3):792-800. PubMed ID: 33400403
[TBL] [Abstract][Full Text] [Related]
19. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
Blonde L; Stenlöf K; Fung A; Xie J; Canovatchel W; Meininger G
Postgrad Med; 2016 May; 128(4):371-80. PubMed ID: 27002421
[TBL] [Abstract][Full Text] [Related]
20. Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: A randomized, double-blind, placebo-controlled study.
Pelusi C; Giagulli VA; Baccini M; Fanelli F; Mezzullo M; Fazzini A; Bianchi N; Carbone MD; De Pergola G; Mastroroberto M; Morselli Labate AM; Pasquali R
PLoS One; 2017; 12(9):e0183369. PubMed ID: 28886024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
